|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11,268 GBX | +0.16% |
|
+3.59% | +6.30% |
| Apr. 23 | AstraZeneca's Voydeya Approved as Add-on Therapy in Europe for Blood Disorder | MT |
| Apr. 23 | ASTRAZENECA : JP Morgan reaffirms its Buy rating | ZD |
LONDON (Reuters) - AstraZeneca has boosted its early-stage research in autoimmune disease by signing a three-year research deal with start-up firm Orca Pharmaceuticals, a small British biotech company formed in 2013, on a new class of drugs.
Orca will receive an upfront payment and further fees from AstraZeneca with a potential total value of $122.5 million, the companies said on Wednesday. Final payments will depend on the success of Orca's so-called retinoic acid–related orphan nuclear receptor gamma inhibitors.
(Reporting by Ben Hirschler; editing by David Clarke)
| 1st Jan change | Capi. | |
|---|---|---|
| +6.30% | 217B | |
| +27.92% | 672B | |
| +27.68% | 570B | |
| -4.59% | 360B | |
| +16.38% | 321B | |
| +9.39% | 300B | |
| +4.80% | 199B | |
| -6.05% | 204B | |
| -8.58% | 149B | |
| -4.99% | 147B |
ASTRAZENECA PLC 
